Historique du chiffre d'affaires, des bénéfices et des flux de trésorerie d'après les états financiers officiels.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage.
Voir les graphiques interactifs et les états complets → Modèle de valorisation (DCF) →
| Compte de résultat | TTM → 2026-07-31 | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 | 2016-10-31 | 2015-10-31 | 2014-10-31 | 2013-10-31 | 2012-10-31 | 2011-10-31 | 2010-10-31 | 2009-10-31 | 2008-10-31 | 2007-10-31 | 2006-10-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiffre d'affaires total | $4.2B | $4.1B | $3.9B | $3.6B | $3.3B | $2.9B | $2.4B | $2.7B | $2.5B | $2.1B | $2.0B | $1.8B | $1.7B | $1.6B | $1.4B | $1.3B | $1.2B | $1.1B | $1.1B | $951M | $859M |
| Bénéfice brut | $2.7B | $2.5B | $2.6B | $2.4B | $2.1B | $2.0B | $1.5B | $1.8B | $1.6B | $1.4B | $1.2B | $1.1B | $1.1B | $1.0B | $924M | $805M | $677M | $596M | $610M | $520M | $526M |
| Marge brute % | 64.7% | 60.7% | 66.6% | 65.6% | 64.7% | 66.9% | 63.1% | 66.2% | 64.5% | 63.8% | 59.6% | 59.6% | 63.5% | 64.7% | 63.9% | 60.5% | 58.4% | 55.2% | 57.4% | 54.6% | 61.2% |
| Résultat opérationnel (EBIT) | $544M | $683M | $706M | $533M | $508M | $506M | $312M | $547M | $403M | $429M | $324M | $237M | $306M | $306M | $283M | $228M | $190M | $150M | $127M | $46M | $113M |
| Marge opérationnelle % | 12.8% | 16.7% | 18.1% | 14.8% | 15.3% | 17.3% | 12.8% | 20.6% | 15.9% | 20.1% | 16.5% | 13.2% | 17.8% | 19.3% | 19.6% | 17.1% | 16.4% | 13.9% | 11.9% | 4.8% | 13.1% |
| Résultat net | $571M | $375M | $392M | $294M | $386M | $2.9B | $238M | $467M | $140M | $373M | $274M | $204M | $270M | $296M | $248M | $175M | $113M | $101M | $65M | ($11M) | $66M |
| Marge nette % | 13.5% | 9.2% | 10.1% | 8.2% | 11.7% | 100.8% | 9.8% | 17.6% | 5.5% | 17.4% | 13.9% | 11.3% | 15.7% | 18.6% | 17.2% | 13.2% | 9.7% | 9.3% | 6.2% | -1.2% | 7.7% |
| EBITDA | — | $1.1B | $1.1B | $886M | $879M | $824M | $590M | $826M | $690M | $616M | $520M | $425M | $443M | $447M | $398M | $308M | $255M | $252M | $209M | $140M | $181M |
| Bénéfice par action (EPS) | $2.93 | $1.87 | $1.96 | $1.48 | $1.94 | $14.77 | $1.20 | $2.33 | $0.70 | $1.88 | $1.40 | $1.03 | $1.38 | $1.49 | $1.26 | $0.91 | $0.61 | $0.55 | $0.35 | $-0.06 | $0.35 |
| Actions en circulation (M) | — | 200M | 200M | 199M | 199M | 199M | 198M | 200M | 199M | 198M | 196M | 197M | 196M | 199M | 197M | 193M | 186M | 182M | 187M | 179M | 190M |
Source : rapports publics de la société (SEC). Vérifiez sur SEC EDGAR avant de vous fier à tout chiffre.
Bilans, flux de trésorerie, données trimestrielles et ratios complets dans le visualiseur interactif de COO. /companies/us/COO
Les informations de ce site sont fournies à des fins éducatives et informatives uniquement ; elles ne constituent pas un conseil en investissement. Aucun objectif de cours ni recommandation n'est publié.
About TickerBase · Data methodology & sources · Privacy · Terms